Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and...

Area of Science:

• Oncology
• Otolaryngology
• Molecular Biology

Background:

• Middle ear and temporal bone adenomatous tumors are rare, morbid, and difficult to detect early.
• Late diagnosis complicates surgical resection, necessitating identification of molecular targets and therapies.

Purpose of the Study:

• To develop and characterize a novel mouse model for aggressive papillary ear tumors.
• To investigate the molecular drivers and therapeutic vulnerabilities of these rare neoplasms.

Main Methods:

• Serendipitous discovery of ear tumors in mice generated for a mutant EGFR-driven lung cancer model.
• Magnetic resonance imaging (MRI) to visualize tumor development and location.
• Analysis of tumor molecular markers, including mutant epidermal growth factor receptor (EGFR) and downstream signaling pathways (Akt, mTOR, ERK1/2).
• Assessment of EGFR-directed therapies for tumor eradication and correction of vestibular dysfunction.

Main Results:

• A mouse model developed aggressive, bilateral papillary ear tumors in the tympanic cavity.
• Tumors expressed mutant EGFR and activated downstream signaling pathways.
• EGFR-directed therapies were highly effective in eradicating tumors and resolving vestibular defects.
• EGFR activation was confirmed in human ear neoplasms, validating the model's clinical relevance.

Conclusions:

• The novel mouse model accurately recapitulates aggressive papillary ear tumors.
• These tumors are dependent on EGFR signaling, presenting a therapeutic vulnerability.
• EGFR-targeted therapies show promise for treating rare ear neoplasms.